O. Fromigue, E. Hay, D. Modrowski, S. Bouvet, A. Jacquel et al., RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation, Cell Death Differ, vol.13, pp.1845-1856, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00146205

O. Fromigue, Z. Hamidouche, and P. J. Marie, Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion, J Biol Chem, vol.283, pp.30549-30556, 2008.

O. Fromigue, Z. Hamidouche, and P. J. Marie, Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase sensitizes human osteosarcoma cells to anticancer drugs, J Pharmacol Exp Ther, vol.325, pp.595-600, 2008.

O. Fromigue, Z. Hamidouche, P. Vaudin, F. Lecanda, A. Patino et al., CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis, J Bone Miner Res, vol.26, pp.1533-1542, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01129595

P. Coyle, J. C. Philcox, L. C. Carey, and A. M. Rofe, Metallothionein: the multipurpose protein, Cell Mol Life Sci, vol.59, pp.627-647, 2002.

B. Ruttkay-nedecky, L. Nejdl, J. Gumulec, O. Zitka, M. Masarik et al., The role of metallothionein in oxidative stress, Int J Mol Sci, vol.14, pp.6044-6066, 2013.

D. Laukens, A. Waeytens, D. Bleser, P. Cuvelier, C. et al., Human metallothionein expression under normal and pathological conditions: mechanisms of gene regulation based on in silico promoter analysis, Crit Rev Eukaryot Gene Exp, vol.19, pp.301-317, 2009.

N. Thirumoorthy, S. Sunder, A. , M. Kumar, K. et al., A review of metallothionein isoforms and their role in pathophysiology, World J Surg Oncol, vol.9, p.54, 2011.

M. Aschner, The functional significance of brain metallothioneins, FASEB J, vol.10, pp.1129-1136, 1996.

Y. Uchida, F. Gomi, T. Masumizu, and Y. Miura, Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging, J Biol Chem, vol.277, pp.32353-32359, 2002.

C. Jacob, W. Maret, and B. L. Vallee, Control of zinc transfer between thionein, metallothionein, and zinc proteins, Proc Natl Acad Sci, vol.95, pp.3489-3494, 1998.

W. Maret and B. L. Vallee, Thiolate ligands in metallothionein confer redox activity on zinc clusters, Proc Natl Acad Sci, vol.95, pp.3478-3482, 1998.

L. J. Jiang, W. Maret, and B. L. Vallee, The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase, Proc Natl Acad Sci, vol.95, pp.3483-3488, 1998.

I. Saboli?, D. Breljak, M. Skarica, and C. M. Herak-kramberger, Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs, Biometals, vol.23, pp.897-926, 2010.

S. L. Kelley, A. Basu, B. A. Teicher, M. P. Hacker, D. H. Hamer et al., Overexpression of metallothionein confers resistance to anticancer drugs, Science, vol.241, pp.1813-1815, 1988.

K. Kasahara, Y. Fujiwara, K. Nishio, T. Ohmori, Y. Sugimoto et al., Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin, Cancer Res, vol.51, pp.3237-3242, 1991.

M. Nakano, C. A. Sogawa, N. Sogawa, K. Mishima, E. Yamachika et al., Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma, Anticancer Res, vol.23, pp.299-303, 2003.

C. H. Choi, Y. J. Cha, C. S. An, K. J. Kim, K. C. Kim et al., Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein, Cancer Cell Int, vol.4, p.6, 2004.

P. Surowiak, V. Materna, A. Maciejczyk, M. Pude"ko, E. Markwitz et al., Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome, Virchows Arch, vol.450, pp.279-285, 2007.

S. Krizkova, M. Masarik, P. Majzlik, J. Kukacka, J. Kruseova et al., Serum metallothionein in newly diagnosed patients with childhood solid tumours, Acta Biochim Pol, vol.57, pp.561-566, 2010.

L. Endo-munoz, A. Cumming, S. Sommerville, I. Dickinson, and N. A. Saunders, Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone, Br J Cancer, vol.103, pp.73-81, 2010.

I. Sturm, A. G. Bosanquet, S. Hermann, D. Güner, B. Dörken et al., Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNAdamaging chemotherapy, Cell Death Differ, vol.10, pp.477-484, 2003.

M. A. Lynes, Y. J. Kang, S. L. Sensi, G. A. Perdrizet, and L. E. Hightower, Heavy metal ions in normal physiology, toxic stress, and cytoprotection, Ann N Y Acad Sci, vol.1113, pp.159-172, 2007.

T. Eckschlager, V. Adam, J. Hrabeta, K. Figova, and R. Kizek, Metallothioneins and cancer, Curr Protein Pept Sci, vol.10, pp.360-375, 2009.

K. Ishii, S. Usui, H. Yamamoto, Y. Sugimura, M. Tatematsu et al., Decreases of metallothionein and aminopeptidase N in renal cancer tissues, J Biochem, vol.129, pp.253-258, 2001.

G. W. Huang and L. Y. Yang, Metallothionein expression in hepatocellular carcinoma, World J Gastroenterol, vol.8, pp.650-653, 2002.

H. Wei, M. M. Desouki, S. Lin, X. D. Franklin, R. B. Feng et al., Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues, Mol Cancer, vol.7, p.7, 2008.

M. Yamaguchi, Role of nutritional zinc in the prevention of osteoporosis, Mol Cell Biochem, vol.338, pp.241-254, 2010.

J. Gumulec, M. Masarik, S. Krizkova, V. Adam, J. Hubalek et al., Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma, Curr Med Chem, vol.18, pp.5041-5051, 2011.

O. Zitka, M. Ryvolova, J. Hubalek, T. Eckschlager, V. Adam et al., From amino acids to proteins as targets for metal-based drugs, Curr Drug Metab, vol.13, pp.306-320, 2012.

S. Krizkova, M. Ryvolova, J. Hrabeta, V. Adam, M. Stiborova et al., Metallothioneins and zinc in cancer diagnosis and therapy, Drug Metab Rev, vol.44, pp.287-301, 2012.

W. Leonhardt, T. Kurktschiev, D. Meissner, P. Lattke, C. Abletshauser et al., Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals, Eur J Clin Pharmacol, vol.53, pp.65-69, 1997.

M. I. Yilmaz, Y. Baykal, M. Kilic, A. Sonmez, F. Bulucu et al., Effects of statins on oxidative stress, Biol Trace Elem Res, vol.98, pp.119-127, 2004.

M. Ghayour-mobarhan, D. J. Lamb, A. Taylor, N. Vaidya, C. Livingstone et al., Effect of statin therapy on serum trace element status in dyslipidaemic subjects, J Trace Elem Med Biol, vol.19, pp.61-67, 2005.

L. Costarelli, E. Muti, M. Malavolta, R. Giacconi, C. Cipriano et al., Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors, Rejuvenation Res, vol.11, pp.287-291, 2008.

M. Nagata and B. Lönnerdal, Role of zinc in cellular zinc trafficking and mineralization in a murine osteoblast-like cell line, J Nutr Biochem, vol.22, pp.172-178, 2011.

H. J. Seo, Y. E. Cho, T. Kim, H. I. Shin, and I. S. Kwun, Zinc may increase bone formation through stimulating cell proliferation, alkaline phosphatase activity and collagen synthesis in osteoblastic MC3T3-E1 cells, Nutr Res Pract, vol.4, pp.356-361, 2010.

Y. Dohi, H. Shimaoka, M. Ikeuchi, H. Ohgushi, K. Yonemasu et al., Role of metallothionein isoforms in bone formation processes in rat marrow mesenchymal stem cells in culture, Biol Trace Elem Res, vol.104, pp.57-70, 2005.

M. Knipp, Metallothioneins and platinum(II) anti-tumor compounds, Curr Med Chem, vol.16, pp.522-537, 2009.

D. B. Zamble and S. J. Lippard, Cisplatin and DNA repair in cancer chemotherapy, Trends Biochem Sci, vol.20, pp.435-439, 1995.

M. M. Webber, S. M. Rehman, and G. T. James, Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin, Cancer Res, vol.48, pp.4503-4508, 1988.

M. Volm, R. Koomägi, J. Mattern, and T. Efferth, Protein expression profiles indicative for drug resistance of non-small cell lung cancer, Br J Cancer, vol.87, pp.251-257, 2002.

X. Yap, H. Y. Tan, J. Huang, Y. Lai, G. W. Yip et al., Over-expression of metallothionein predicts chemoresistance in breast cancer, J Pathol, vol.217, pp.563-570, 2009.

D. Wysokinski, J. Blasiak, and K. Wozniak, Zinc differentially modulates DNA damage induced by anthracyclines in normal and cancer cells, Exp Oncol, vol.34, pp.327-331, 2012.

B. Vogelstein, D. Lane, and A. J. Levine, Surfing the p53 network, Nature, vol.408, pp.307-310, 2000.

K. H. Vousden and X. Lu, Live or let die: the cell's response to p53, Nat Rev Cancer, vol.2, pp.594-604, 2002.

S. Knappskog and P. E. Lønning, P53 and its molecular basis to chemoresistance in breast cancer, Expert Opin Ther Targets, vol.16, issue.1, pp.23-30, 2012.

A. B. Abdel-mageed and K. C. Agrawal, Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response, Cancer Res, vol.58, pp.2335-2338, 1998.

E. A. Ostrakhovitch, P. E. Olsson, S. Jiang, and M. G. Cherian, Interaction of metallothionein with tumor suppressor p53 protein, FEBS Lett, vol.580, pp.1235-1238, 2006.

N. Xia, L. Liu, X. Yi, and J. Wang, Studies of interaction of tumor suppressor p53 with apo-MT using surface plasmon resonance, Anal Bioanal Chem, vol.395, pp.2569-2575, 2009.

C. Méplan, G. Verhaegh, M. J. Richard, and P. Hainaut, Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis, Proc Nutr Soc, vol.58, pp.565-571, 1999.

J. Wang and J. Yang, Interaction of tumor suppressor p53 with DNA and proteins, Curr Pharm Biotechnol, vol.11, pp.122-127, 2010.

S. D. Shnyder, A. J. Hayes, J. Pringle, and C. W. Archer, P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma, Br J Cancer, vol.78, pp.757-759, 1998.

A. K. Sewell, L. T. Jensen, J. C. Erickson, R. D. Palmiter, and D. R. Winge, Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties, Biochemistry, vol.34, pp.4740-4747, 1995.

Z. Hamidouche, E. Haÿ, P. Vaudin, P. Charbord, R. Schüle et al., FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression, FASEB J, vol.22, pp.3813-3822, 2008.

O. Fromigue, L. Lagneaux, and J. J. Body, Bisphosphonates induce breast cancer cell death in vitro, J Bone Miner Res, vol.15, pp.2211-2221, 2000.

A. Patiño-garcía, M. Zalacain, C. Folio, C. Zandueta, L. Sierrasesúmaga et al., Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis, Clin Cancer Res, vol.15, pp.5082-5091, 2009.

A. G. Huvos, G. Rosen, and R. C. Marcove, Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement, Arch Pathol Lab Med, vol.101, pp.14-18, 1977.